KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueEBIATLeasesOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetReceivables - Other
Ratios

Rigel Pharmaceuticals (RIGL) EBIAT (2016 - 2025)

Rigel Pharmaceuticals (RIGL) has 16 years of EBIAT data on record, last reported at $268.1 million in Q4 2025.

  • For Q4 2025, EBIAT rose 1769.22% year-over-year to $268.1 million; the TTM value through Dec 2025 reached $367.0 million, up 1999.08%, while the annual FY2025 figure was $367.0 million, 1999.08% up from the prior year.
  • EBIAT reached $268.1 million in Q4 2025 per RIGL's latest filing, up from $27.9 million in the prior quarter.
  • Across five years, EBIAT topped out at $268.1 million in Q4 2025 and bottomed at -$27.4 million in Q1 2022.
  • Average EBIAT over 5 years is $14.1 million, with a median of -$3.4 million recorded in 2023.
  • Peak YoY movement for EBIAT: plummeted 169.48% in 2022, then soared 5887.67% in 2025.
  • A 5-year view of EBIAT shows it stood at -$22.6 million in 2021, then skyrocketed by 106.19% to $1.4 million in 2022, then plummeted by 47.39% to $737000.0 in 2023, then soared by 1845.86% to $14.3 million in 2024, then surged by 1769.22% to $268.1 million in 2025.
  • Per Business Quant database, its latest 3 readings for EBIAT were $268.1 million in Q4 2025, $27.9 million in Q3 2025, and $59.6 million in Q2 2025.